San Francisco, California, August 01, 2017: Considering how common viral conjunctivitis is, the demand for medications to speed up its recovery is high. The incidence of viral conjunctivitis is less likely to subside in the coming years, following which, experts forecast steady growth for the global viral conjunctivitis market. In a report, titled “Viral Conjunctivitis Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025,” TMR Research provides a comprehensive overview of the market, underlining the various factors influencing its trajectory this far.
The report compiles exhaustive information sourced via proven research methodologies. To provide a holistic overview, information provided in the report is substantiated using relevant graph, statistics, and infographs. Furthermore, expert opinions form a very important part of the report. Information thus provided is intended to help stakeholders have a more comprehensive overview of the global viral conjunctivitis market.
TMR Research forecasts the global viral conjunctivitis market to progress at a full tilt, deriving growth primarily from the high incidence of eye disorders. Viral conjunctivitis constitute a major portion of the acute conjunctivitis witnessed worldwide, finds TMR Research. The growing awareness regarding the same will positively influence the market. Besides this research and development of novel medications to prevent and treat viral conjunctivitis will give significant impetus to the market in the coming years. Government initiatives in this regard have been commendable. Especially across developing and underdeveloped nations, governments have focused their efforts toward educating people about viral conjunctivitis, its symptoms, and common treatment methods.
For instance, the Public Health Ministry of Lebanon has commenced a campaign for spreading awareness about the diseases in association with the Ministry of Education and Higher Learning. Such initiatives will emerge as chief market drivers in the coming years. According to statistics revealed by the US government authority, nearly 5 million cases of viral conjunctivitis are reported every year. Furthermore, about US$589 million is spent every year in the treatment of viral conjunctivitis. While the statistics indicate high incidence of the disease, a factor that will aid the market’s expansion, lack of awareness could hinder the market’s growth across remote locations.
Pfizer Inc., Allergan Inc., Merck & Co., and Novartis are some of the most prominent vendors operating in the global viral conjunctivitis market. Besides this, the market exhibits the presence of a large number of companies, which is indicative of its fragmented vendor landscape. To gain a stronghold a majority of players are keen on mergers, acquisitions, and strategic collaborations. The report profiles the leading companies operating in the global viral conjunctivitis market, discussing in detail their product portfolio, financial overview, strategic collaborations, and marketing strategies. The report is therefore intended to enable companies take informed decision to capitalize on the prevailing market trends.
Click on the link below to request a sample copy of the report